Summary

The global bile duct cancer treatment market is poised for substantial expansion, projected to rise from US$ 4.4 billion in 2025 to US$ 8.1 billion by 2032. This impressive growth trajectory represents a robust CAGR of 9.11% during the forecast period. Growing awareness, technological progress in diagnostics, and the emergence of targeted and immunotherapy treatments are expected to reshape the therapeutic Analysis for bile duct cancer.

Market Insights

Cholangiocarcinoma, the most common form of bile duct cancer, is witnessing a surge in global cases. The market is responding with a dynamic evolution in treatment protocols, including surgery, chemotherapy, radiation, immunotherapies, and precision-targeted therapies. Advances in liquid biopsies, genetic profiling, and AI-powered diagnostics are significantly improving early detection and individualized treatment.

With a shift towards personalized medicine, major pharmaceutical companies are investing in targeted therapies like kinase inhibitors and immunotherapies. Additionally, surgical intervention continues to hold relevance for intrahepatic cholangiocarcinoma, where early diagnosis allows resection with curative intent.

Key Market Drivers

One of the primary drivers of this market is the rising global prevalence of bile duct cancer due to aging populations, obesity, diabetes, and chronic liver disease. Furthermore, the following key factors are accelerating market development:

• Surge in Immunotherapy Research: Immunotherapies such as checkpoint inhibitors are showing positive long-term results, particularly for advanced-stage cholangiocarcinoma. Trials involving drugs like nivolumab have shown extended progression-free survival and overall survival rates.

• Improved Diagnostics: The emergence of cutting-edge diagnostics such as HER2 companion diagnostics and biomarker-based detection is contributing to timely diagnosis and personalized treatment regimens.

• Patient Awareness and Screening: Public health awareness programs and advances in non-invasive screening techniques have improved early-stage diagnosis, increasing the number of patients eligible for curative treatment.

Business Opportunity

The increasing demand for innovative therapies presents significant opportunities for new entrants and existing players in the oncology space. Collaborative research between biopharmaceutical companies and academic institutions is accelerating the development of advanced drugs, including dual-targeted antibodies and kinase inhibitors.

Emerging players focusing on immunotherapy and molecular-targeted therapies can capitalize on unmet clinical needs. Clinical trials backed by genomic data and AI-assisted screening tools are key to identifying niche segments within bile duct cancer and delivering more effective, tailored treatments.

Governments and global health organizations are also supporting innovation through funding and regulatory streamlining, promoting growth opportunities for stakeholders.

Regional Analysis

North America is expected to dominate the global bile duct cancer treatment market throughout the forecast period. The region benefits from early diagnosis programs, cutting-edge research infrastructure, and favorable reimbursement policies. With an established base of biopharmaceutical companies and high healthcare spending, North America continues to lead innovation in oncology care.

Asia Pacific follows as a promising market, with rising healthcare expenditure and growing awareness contributing to increased demand. The region’s rapid economic development, expanding telemedicine services, and growing focus on universal health coverage are supporting the adoption of advanced cancer treatments.

Europe also maintains a strong presence due to its robust clinical research network and investments in personalized medicine and rare cancer treatment solutions.

Key Players

Key players shaping the competitive Analysis include Pfizer, F. Hoffmann-La Roche, Bristol-Myers Squibb, Teva Pharmaceuticals, Eli Lilly, Novartis, Sanofi, and Johnson & Johnson. These companies are actively involved in R&D, clinical trials, strategic collaborations, and drug innovations in oncology.

Emerging biopharma firms like Incyte and Mirati Therapeutics are focusing on niche therapies and targeted treatments for specific genetic mutations in bile duct cancer. The market also witnesses increasing partnerships between pharma companies and research institutes for pipeline expansion and faster approvals.

Market Segmentation

By Treatment Type

• Chemotherapy (Gemcitabine-based, Cisplatin-based, Combination therapies, Others)

• Targeted Therapy (EGFR Inhibitors, VEGF Inhibitors, Others)

• Radiation Therapy

• Immunotherapy

• Surgery

• Others

By Disease Type

• Intrahepatic Cholangiocarcinoma

• Extrahepatic Cholangiocarcinoma

• Perihilar Cholangiocarcinoma (Klatskin tumors)

• Distal Cholangiocarcinoma

By Distribution Channel

• Hospital Pharmacies

• Retail Pharmacies

• Online Pharmacies

By Region

• North America

• Europe

• East Asia

• South Asia and Oceania

• Latin America

• Middle East and Africa

ページTOPに戻る

Table of Contents

1. Executive Summary
1.1. Global Bile Duct Cancer Treatment Market Snapshot
1.2. Future Projections
1.3. Key Market Trends
1.4. Regional Snapshot, by Value, 2025
1.5. Analyst Recommendations
2. Market Overview
2.1. Market Definitions and Segmentations
2.2. Market Dynamics
2.2.1. Drivers
2.2.2. Restraints
2.2.3. Market Opportunities
2.3. Value Chain Analysis
2.4. Porter’s Five Forces Analysis
2.5. COVID-19 Impact Analysis
2.5.1. Supply
2.5.2. Demand
2.6. Impact of Ukraine-Russia Conflict
2.7. Economic Overview
2.7.1. World Economic Projections
2.8. PESTLE Analysis
3. Global Bile Duct Cancer Treatment Market Outlook, 2019-2032
3.1. Global Bile Duct Cancer Treatment Market Outlook, by Treatment Type, Value (US$ Bn), 2019-2032
3.1.1. Key Highlights
3.1.1.1. Treatment
3.1.1.2. Services Spending
3.1.1.3. Radiation Therapy
3.1.1.4. Surgery
3.2. Global Bile Duct Cancer Treatment Market Outlook, by Disease Indication, Value (US$ Bn), 2019-2032
3.2.1. Key Highlights
3.2.1.1. Intrahepatic Bile Duct Cancer
3.2.1.2. Extrahepatic Bile Duct Cancer
3.2.1.2.1. Perihilar Bile Duct Cancer
3.2.1.2.2. Distal Extrahepatic Bile Duct Cancer
3.3. Global Bile Duct Cancer Treatment Market Outlook, by Distribution Channel, Value (US$ Bn), 2019-2032
3.3.1. Key Highlights
3.3.1.1. Hospital Pharmacies
3.3.1.2. Retail Pharmacies
3.3.1.3. Online Pharmacies
3.4. Global Bile Duct Cancer Treatment Market Outlook, by Region, Value (US$ Bn), 2019-2032
3.4.1. Key Highlights
3.4.1.1. North America
3.4.1.2. Europe
3.4.1.3. Asia Pacific
3.4.1.4. Latin America
3.4.1.5. Middle East & Africa
4. North America Bile Duct Cancer Treatment Market Outlook, 2019-2032
4.1. North America Bile Duct Cancer Treatment Market Outlook, by Treatment Type, Value (US$ Bn), 2019-2032
4.1.1. Key Highlights
4.1.1.1. Treatment
4.1.1.2. Services Spending
4.1.1.3. Radiation Therapy
4.1.1.4. Surgery
4.2. North America Bile Duct Cancer Treatment Market Outlook, by Disease Indication, Value (US$ Bn), 2019-2032
4.2.1. Key Highlights
4.2.1.1. Intrahepatic Bile Duct Cancer
4.2.1.2. Extrahepatic Bile Duct Cancer
4.2.1.2.1. Perihilar Bile Duct Cancer
4.2.1.2.2. Distal Extrahepatic Bile Duct Cancer
4.3. North America Bile Duct Cancer Treatment Market Outlook, by Distribution Channel, Value (US$ Bn), 2019-2032
4.3.1. Key Highlights
4.3.1.1. Hospital Pharmacies
4.3.1.2. Retail Pharmacies
4.3.1.3. Online Pharmacies
4.3.2. BPS Analysis/Market Attractiveness Analysis
4.4. North America Bile Duct Cancer Treatment Market Outlook, by Country, Value (US$ Bn), 2019-2032
4.4.1. Key Highlights
4.4.1.1. U.S. Bile Duct Cancer Treatment Market by Treatment Type, Value (US$ Bn), 2019-2032
4.4.1.2. U.S. Bile Duct Cancer Treatment Market by Disease Indication, Value (US$ Bn), 2019-2032
4.4.1.3. U.S. Bile Duct Cancer Treatment Market by Distribution Channel, Value (US$ Bn), 2019-2032
4.4.1.4. Canada Bile Duct Cancer Treatment Market by Treatment Type, Value (US$ Bn), 2019-2032
4.4.1.5. Canada Bile Duct Cancer Treatment Market by Disease Indication, Value (US$ Bn), 2019-2032
4.4.1.6. Canada Bile Duct Cancer Treatment Market by Distribution Channel, Value (US$ Bn), 2019-2032
4.4.2. BPS Analysis/Market Attractiveness Analysis
5. Europe Bile Duct Cancer Treatment Market Outlook, 2019-2032
5.1. Europe Bile Duct Cancer Treatment Market Outlook, by Treatment Type, Value (US$ Bn), 2019-2032
5.1.1. Key Highlights
5.1.1.1. Treatment
5.1.1.2. Services Spending
5.1.1.3. Radiation Therapy
5.1.1.4. Surgery
5.2. Europe Bile Duct Cancer Treatment Market Outlook, by Disease Indication, Value (US$ Bn), 2019-2032
5.2.1. Key Highlights
5.2.1.1. Intrahepatic Bile Duct Cancer
5.2.1.2. Extrahepatic Bile Duct Cancer
5.2.1.2.1. Perihilar Bile Duct Cancer
5.2.1.2.2. Distal Extrahepatic Bile Duct Cancer
5.3. Europe Bile Duct Cancer Treatment Market Outlook, by Distribution Channel, Value (US$ Bn), 2019-2032
5.3.1. Key Highlights
5.3.1.1. Hospital Pharmacies
5.3.1.2. Retail Pharmacies
5.3.1.3. Online Pharmacies
5.3.2. BPS Analysis/Market Attractiveness Analysis
5.4. Europe Bile Duct Cancer Treatment Market Outlook, by Country, Value (US$ Bn), 2019-2032
5.4.1. Key Highlights
5.4.1.1. Germany Bile Duct Cancer Treatment Market by Treatment Type, Value (US$ Bn), 2019-2032
5.4.1.2. Germany Bile Duct Cancer Treatment Market by Disease Indication, Value (US$ Bn), 2019-2032
5.4.1.3. Germany Bile Duct Cancer Treatment Market by Distribution Channel, Value (US$ Bn), 2019-2032
5.4.1.4. U.K. Bile Duct Cancer Treatment Market by Treatment Type, Value (US$ Bn), 2019-2032
5.4.1.5. U.K. Bile Duct Cancer Treatment Market by Disease Indication, Value (US$ Bn), 2019-2032
5.4.1.6. U.K. Bile Duct Cancer Treatment Market by Distribution Channel, Value (US$ Bn), 2019-2032
5.4.1.7. France Bile Duct Cancer Treatment Market by Treatment Type, Value (US$ Bn), 2019-2032
5.4.1.8. France Bile Duct Cancer Treatment Market by Disease Indication, Value (US$ Bn), 2019-2032
5.4.1.9. France Bile Duct Cancer Treatment Market by Distribution Channel, Value (US$ Bn), 2019-2032
5.4.1.10. Italy Bile Duct Cancer Treatment Market by Treatment Type, Value (US$ Bn), 2019-2032
5.4.1.11. Italy Bile Duct Cancer Treatment Market by Disease Indication, Value (US$ Bn), 2019-2032
5.4.1.12. Italy Bile Duct Cancer Treatment Market by Distribution Channel, Value (US$ Bn), 2019-2032
5.4.1.13. Turkey Bile Duct Cancer Treatment Market by Treatment Type, Value (US$ Bn), 2019-2032
5.4.1.14. Turkey Bile Duct Cancer Treatment Market by Disease Indication, Value (US$ Bn), 2019-2032
5.4.1.15. Turkey Bile Duct Cancer Treatment Market by Distribution Channel, Value (US$ Bn), 2019-2032
5.4.1.16. Russia Bile Duct Cancer Treatment Market by Treatment Type, Value (US$ Bn), 2019-2032
5.4.1.17. Russia Bile Duct Cancer Treatment Market by Disease Indication, Value (US$ Bn), 2019-2032
5.4.1.18. Russia Bile Duct Cancer Treatment Market by Distribution Channel, Value (US$ Bn), 2019-2032
5.4.1.19. Rest of Europe Bile Duct Cancer Treatment Market by Treatment Type, Value (US$ Bn), 2019-2032
5.4.1.20. Rest of Europe Bile Duct Cancer Treatment Market by Disease Indication, Value (US$ Bn), 2019-2032
5.4.1.21. Rest of Europe Bile Duct Cancer Treatment Market by Distribution Channel, Value (US$ Bn), 2019-2032
5.4.2. BPS Analysis/Market Attractiveness Analysis
6. Asia Pacific Bile Duct Cancer Treatment Market Outlook, 2019-2032
6.1. Asia Pacific Bile Duct Cancer Treatment Market Outlook, by Treatment Type, Value (US$ Bn), 2019-2032
6.1.1. Key Highlights
6.1.1.1. Treatment
6.1.1.2. Services Spending
6.1.1.3. Radiation Therapy
6.1.1.4. Surgery
6.2. Asia Pacific Bile Duct Cancer Treatment Market Outlook, by Disease Indication, Value (US$ Bn), 2019-2032
6.2.1. Key Highlights
6.2.1.1. Intrahepatic Bile Duct Cancer
6.2.1.2. Extrahepatic Bile Duct Cancer
6.2.1.2.1. Perihilar Bile Duct Cancer
6.2.1.2.2. Distal Extrahepatic Bile Duct Cancer
6.3. Asia Pacific Bile Duct Cancer Treatment Market Outlook, by Distribution Channel, Value (US$ Bn), 2019-2032
6.3.1. Key Highlights
6.3.1.1. Hospital Pharmacies
6.3.1.2. Retail Pharmacies
6.3.1.3. Online Pharmacies
6.3.2. BPS Analysis/Market Attractiveness Analysis
6.4. Asia Pacific Bile Duct Cancer Treatment Market Outlook, by Country, Value (US$ Bn), 2019-2032
6.4.1. Key Highlights
6.4.1.1. China Bile Duct Cancer Treatment Market by Treatment Type, Value (US$ Bn), 2019-2032
6.4.1.2. China Bile Duct Cancer Treatment Market by Disease Indication, Value (US$ Bn), 2019-2032
6.4.1.3. China Bile Duct Cancer Treatment Market by Distribution Channel, Value (US$ Bn), 2019-2032
6.4.1.4. Japan Bile Duct Cancer Treatment Market by Treatment Type, Value (US$ Bn), 2019-2032
6.4.1.5. Japan Bile Duct Cancer Treatment Market by Disease Indication, Value (US$ Bn), 2019-2032
6.4.1.6. Japan Bile Duct Cancer Treatment Market by Distribution Channel, Value (US$ Bn), 2019-2032
6.4.1.7. South Korea Bile Duct Cancer Treatment Market by Treatment Type, Value (US$ Bn), 2019-2032
6.4.1.8. South Korea Bile Duct Cancer Treatment Market by Disease Indication, Value (US$ Bn), 2019-2032
6.4.1.9. South Korea Bile Duct Cancer Treatment Market by Distribution Channel, Value (US$ Bn), 2019-2032
6.4.1.10. India Bile Duct Cancer Treatment Market by Treatment Type, Value (US$ Bn), 2019-2032
6.4.1.11. India Bile Duct Cancer Treatment Market by Disease Indication, Value (US$ Bn), 2019-2032
6.4.1.12. India Bile Duct Cancer Treatment Market by Distribution Channel, Value (US$ Bn), 2019-2032
6.4.1.13. Southeast Asia Bile Duct Cancer Treatment Market by Treatment Type, Value (US$ Bn), 2019-2032
6.4.1.14. Southeast Asia Bile Duct Cancer Treatment Market by Disease Indication, Value (US$ Bn), 2019-2032
6.4.1.15. Southeast Asia Bile Duct Cancer Treatment Market by Distribution Channel, Value (US$ Bn), 2019-2032
6.4.1.16. Rest of Asia Pacific Bile Duct Cancer Treatment Market by Treatment Type, Value (US$ Bn), 2019-2032
6.4.1.17. Rest of Asia Pacific Bile Duct Cancer Treatment Market by Disease Indication, Value (US$ Bn), 2019-2032
6.4.1.18. Rest of Asia Pacific Bile Duct Cancer Treatment Market by Distribution Channel, Value (US$ Bn), 2019-2032
6.4.2. BPS Analysis/Market Attractiveness Analysis
7. Latin America Bile Duct Cancer Treatment Market Outlook, 2019-2032
7.1. Latin America Bile Duct Cancer Treatment Market Outlook, by Treatment Type, Value (US$ Bn), 2019-2032
7.1.1. Key Highlights
7.1.1.1. Treatment
7.1.1.2. Services Spending
7.1.1.3. Radiation Therapy
7.1.1.4. Surgery
7.2. Latin America Bile Duct Cancer Treatment Market Outlook, by Disease Indication, Value (US$ Bn), 2019-2032
7.2.1.1. Intrahepatic Bile Duct Cancer
7.2.1.2. Extrahepatic Bile Duct Cancer
7.2.1.2.1. Perihilar Bile Duct Cancer
7.2.1.2.2. Distal Extrahepatic Bile Duct Cancer
7.3. Latin America Bile Duct Cancer Treatment Market Outlook, by Distribution Channel, Value (US$ Bn), 2019-2032
7.3.1. Key Highlights
7.3.1.1. Hospital Pharmacies
7.3.1.2. Retail Pharmacies
7.3.1.3. Online Pharmacies
7.3.2. BPS Analysis/Market Attractiveness Analysis
7.4. Latin America Bile Duct Cancer Treatment Market Outlook, by Country, Value (US$ Bn), 2019-2032
7.4.1. Key Highlights
7.4.1.1. Brazil Bile Duct Cancer Treatment Market by Treatment Type, Value (US$ Bn), 2019-2032
7.4.1.2. Brazil Bile Duct Cancer Treatment Market by Disease Indication, Value (US$ Bn), 2019-2032
7.4.1.3. Brazil Bile Duct Cancer Treatment Market by Distribution Channel, Value (US$ Bn), 2019-2032
7.4.1.4. Mexico Bile Duct Cancer Treatment Market by Treatment Type, Value (US$ Bn), 2019-2032
7.4.1.5. Mexico Bile Duct Cancer Treatment Market by Disease Indication, Value (US$ Bn), 2019-2032
7.4.1.6. Mexico Bile Duct Cancer Treatment Market by Distribution Channel, Value (US$ Bn), 2019-2032
7.4.1.7. Argentina Bile Duct Cancer Treatment Market by Treatment Type, Value (US$ Bn), 2019-2032
7.4.1.8. Argentina Bile Duct Cancer Treatment Market by Disease Indication, Value (US$ Bn), 2019-2032
7.4.1.9. Argentina Bile Duct Cancer Treatment Market by Distribution Channel, Value (US$ Bn), 2019-2032
7.4.1.10. Rest of Latin America Bile Duct Cancer Treatment Market by Treatment Type, Value (US$ Bn), 2019-2032
7.4.1.11. Rest of Latin America Bile Duct Cancer Treatment Market by Disease Indication, Value (US$ Bn), 2019-2032
7.4.1.12. Rest of Latin America Bile Duct Cancer Treatment Market by Distribution Channel, Value (US$ Bn), 2019-2032
7.4.2. BPS Analysis/Market Attractiveness Analysis
8. Middle East & Africa Bile Duct Cancer Treatment Market Outlook, 2019-2032
8.1. Middle East & Africa Bile Duct Cancer Treatment Market Outlook, by Treatment Type, Value (US$ Bn), 2019-2032
8.1.1. Key Highlights
8.1.1.1. Treatment
8.1.1.2. Services Spending
8.1.1.3. Radiation Therapy
8.1.1.4. Surgery
8.2. Middle East & Africa Bile Duct Cancer Treatment Market Outlook, by Disease Indication, Value (US$ Bn), 2019-2032
8.2.1. Key Highlights
8.2.1.1. Intrahepatic Bile Duct Cancer
8.2.1.2. Extrahepatic Bile Duct Cancer
8.2.1.2.1. Perihilar Bile Duct Cancer
8.2.1.2.2. Distal Extrahepatic Bile Duct Cancer
8.3. Middle East & Africa Bile Duct Cancer Treatment Market Outlook, by Distribution Channel, Value (US$ Bn), 2019-2032
8.3.1. Key Highlights
8.3.1.1. Hospital Pharmacies
8.3.1.2. Retail Pharmacies
8.3.1.3. Online Pharmacies
8.3.2. BPS Analysis/Market Attractiveness Analysis
8.4. Middle East & Africa Bile Duct Cancer Treatment Market Outlook, by Country, Value (US$ Bn), 2019-2032
8.4.1. Key Highlights
8.4.1.1. GCC Bile Duct Cancer Treatment Market by Treatment Type, Value (US$ Bn), 2019-2032
8.4.1.2. GCC Bile Duct Cancer Treatment Market by Disease Indication, Value (US$ Bn), 2019-2032
8.4.1.3. GCC Bile Duct Cancer Treatment Market by Distribution Channel, Value (US$ Bn), 2019-2032
8.4.1.4. South Africa Bile Duct Cancer Treatment Market by Treatment Type, Value (US$ Bn), 2019-2032
8.4.1.5. South Africa Bile Duct Cancer Treatment Market by Disease Indication, Value (US$ Bn), 2019-2032
8.4.1.6. South Africa Bile Duct Cancer Treatment Market by Distribution Channel, Value (US$ Bn), 2019-2032
8.4.1.7. Egypt Bile Duct Cancer Treatment Market by Treatment Type, Value (US$ Bn), 2019-2032
8.4.1.8. Egypt Bile Duct Cancer Treatment Market by Disease Indication, Value (US$ Bn), 2019-2032
8.4.1.9. Egypt Bile Duct Cancer Treatment Market by Distribution Channel, Value (US$ Bn), 2019-2032
8.4.1.10. Nigeria Bile Duct Cancer Treatment Market by Treatment Type, Value (US$ Bn), 2019-2032
8.4.1.11. Nigeria Bile Duct Cancer Treatment Market by Disease Indication, Value (US$ Bn), 2019-2032
8.4.1.12. Nigeria Bile Duct Cancer Treatment Market by Distribution Channel, Value (US$ Bn), 2019-2032
8.4.1.13. Rest of Middle East & Africa Bile Duct Cancer Treatment Market by Treatment Type, Value (US$ Bn), 2019-2032
8.4.1.14. Rest of Middle East & Africa Bile Duct Cancer Treatment Market by Disease Indication, Value (US$ Bn), 2019-2032
8.4.1.15. Rest of Middle East & Africa Bile Duct Cancer Treatment Market by Distribution Channel, Value (US$ Bn), 2019-2032
8.4.2. BPS Analysis/Market Attractiveness Analysis
9. Competitive Landscape
9.1. By Distribution Channel vs by Disease Indication Heat map
9.2. Manufacturer vs by Disease Indication Heatmap
9.3. Company Market Share Analysis, 2025
9.4. Competitive Dashboard
9.5. Company Profiles
9.5.1. Pfizer, Inc.
9.5.1.1. Company Overview
9.5.1.2. Product Portfolio
9.5.1.3. Financial Overview
9.5.1.4. Business Strategies and Development
9.5.2. Hoffman-La Roche AG
9.5.2.1. Company Overview
9.5.2.2. Product Portfolio
9.5.2.3. Financial Overview
9.5.2.4. Business Strategies and Development
9.5.3. Bristol-Myers Squibb Company
9.5.3.1. Company Overview
9.5.3.2. Product Portfolio
9.5.3.3. Financial Overview
9.5.3.4. Business Strategies and Development
9.5.4. Teva Pharmaceuticals Industries Ltd.
9.5.4.1. Company Overview
9.5.4.2. Product Portfolio
9.5.4.3. Financial Overview
9.5.4.4. Business Strategies and Development
9.5.5. Eli Lilly and Company
9.5.5.1. Company Overview
9.5.5.2. Product Portfolio
9.5.5.3. Financial Overview
9.5.5.4. Business Strategies and Development
9.5.6. Novartis AG
9.5.6.1. Company Overview
9.5.6.2. Product Portfolio
9.5.6.3. Financial Overview
9.5.6.4. Business Strategies and Development
9.5.7. Sanofi
9.5.7.1. Company Overview
9.5.7.2. Product Portfolio
9.5.7.3. Financial Overview
9.5.7.4. Business Strategies and Development
9.5.8. Fresenius Kabi AG
9.5.8.1. Company Overview
9.5.8.2. Product Portfolio
9.5.8.3. Financial Overview
9.5.8.4. Business Strategies and Development
9.5.9. Mylan N.V.
9.5.9.1. Company Overview
9.5.9.2. Product Portfolio
9.5.9.3. Financial Overview
9.5.9.4. Business Strategies and Development
9.5.10. Kyowa Hakko Kirin Co Ltd.
9.5.10.1. Company Overview
9.5.10.2. Product Portfolio
9.5.10.3. Financial Overview
9.5.10.4. Business Strategies and Development
9.5.11. Intercept Pharmaceuticals, Inc.
9.5.11.1. Company Overview
9.5.11.2. Product Portfolio
9.5.11.3. Financial Overview
9.5.11.4. Business Strategies and Development
10. Appendix
10.1. Research Methodology
10.2. Report Assumptions
10.3. Acronyms and Abbreviations